It can. But not often, and not permanently. Stage I disease on active surveillance has a recurrence rate of 15 to 20 percent. Add a single cycle of adjuvant chemo and that drops below 5. Most recurrences happen within the first two years. After five years without a sign? The risk is very small. And here’s the part most patients don’t know going in. Even when testicular cancer comes back, it usually still responds to treatment.

According to Prof. Dr. Sandeep Nayak, Surgical Oncologist in India, “The fear of recurrence after testicular cancer is understandable. But the honest answer? Even if it comes back, it’s usually curable. The tumour markers catch it early, weeks before any scan shows something. The surveillance schedule isn’t just monitoring. It’s the safety net. And it works.”

Stage, type, and what the pathology showed. All three matter.

• Stage I on surveillance: Around 15 to 20 percent of stage I non-seminoma patients on active surveillance relapse. Seminoma runs about the same. Not everyone. But enough that the follow up schedule isn’t optional.
• Adjuvant treatment cuts it sharply: One cycle of BEP for non-seminoma or one to two cycles of carboplatin for seminoma after surgery drops recurrence risk below 5 percent. A small trade-off for a lot of peace of mind.
• Lymph node involvement: Positive retroperitoneal nodes push this into stage II territory. Surveillance alone isn’t standard here. RPLND or chemotherapy gets added.
• Tumour biology details: Lymphovascular invasion, elevated AFP or beta-hCG, high embryonal carcinoma content. These findings in the pathology report push the team toward adjuvant treatment rather than just watching.

For patients whose surveillance or recurrence workup leads to a surgical reassessment of lymph nodes, robotic cancer surgery brings minimally invasive RPLND precision with faster recovery.

Markers first. Scans next. Chemotherapy when needed.

• Tumour markers drawn every visit: AFP and beta-hCG normalise after surgery. A rising number afterwards is the earliest warning. Weeks before anything shows on imaging. That’s why skipping the blood test isn’t an option.
• CT scan schedule: Chest, abdomen, pelvis every 3 to 4 months for the first two years. Then less often. The retroperitoneal lymph nodes are the most common place for relapse to appear first.
• BEP chemotherapy: Three to four cycles of bleomycin, etoposide and cisplatin. Highly effective even for advanced recurrent disease. Cure rates for relapsed testicular cancer sit above 70 percent.
• Second primary risk: The other testicle carries a 2 to 5 percent lifetime risk of a new cancer. Different from recurrence but equally important. Monthly self-examination and any new lump reported promptly.

For a full picture of testicular cancer from diagnosis through to treatment options, our blog on testicular cancer covers the complete picture.

Dr. Sandeep Nayak has spent 24 years in surgical oncology. He holds DNB qualifications in Surgical Oncology and General Surgery, plus a fellowship in Laparoscopic and Robotic Onco Surgery. He performs radical inguinal orchiectomy and minimally invasive RPLND for testicular cancer, guides post-surgical surveillance and adjuvant therapy decisions through the tumour board, and counsels patients on recurrence risk, follow up schedule and second primary monitoring. Every testicular cancer case is reviewed by the tumour board before the treatment plan is finalised.

That recurrence risk conversation at the first appointment, not as an afterthought weeks later, is what lets patients go into surveillance with a clear plan rather than ongoing anxiety. Call +91 8104310753 to book your consultation.

Disclaimer: This blog is for informational purposes only and is not a substitute for professional medical advice.

Resection is better when the liver behind the tumour is healthy enough to function after part of it is removed. Transplant is better when the liver itself is diseased, usually cirrhotic, and the tumour fits within the size and number criteria that make recurrence after a donated organ unlikely. Both can cure liver cancer. The tumour is rarely the only deciding factor. The liver’s own health decides as much as the cancer does.

According to Prof. Dr. Sandeep Nayak, Surgical Oncologist in India, “Liver resection and transplant are not competing options. They’re answers to different clinical questions. Resection asks whether the tumour can be removed with enough healthy liver left behind. Transplant asks whether the cancer fits within criteria where recurrence after a donated organ is unlikely enough to justify using it. The tumour board weighs both before recommending either.”

Good liver function behind the tumour changes everything.

• Healthy underlying liver: Child-Pugh A function, no significant portal hypertension. The remnant liver regenerates. Patients with cirrhosis are at much higher risk for post-resection failure. That’s the key dividing line between who resects and who doesn’t.
• Resectable tumour anatomy: Single or limited tumours not hugging major vessels or bile ducts. Clear margins needed. At least 20 to 30 percent functional liver volume must remain after the resection.
• No donor, no waiting: Resection is available now. No list. No matching. No lifelong immunosuppression afterwards. For patients with good liver function and resectable disease, that’s a real practical advantage.
• Beyond Milan but still confined: Tumours too large for transplant criteria but still within the liver can be resected when function holds up. These patients don’t have a transplant path without downstaging first.

For patients whose liver cancer is removed using minimally invasive approaches, robotic cancer surgery brings precision hepatectomy with lower blood loss and faster recovery than open liver resection.

• Milan criteria define transplant eligibility: Single tumour under 5 cm, or up to three tumours none exceeding 3 cm, no vascular invasion, no spread outside the liver. Within these criteria 5-year post-transplant survival exceeds 70 percent.
• Recurrence after resection in cirrhotic liver: Runs 50 to 70 percent at 5 years. Not because surgery failed. The remaining diseased liver keeps generating new tumours. Transplant removes that substrate entirely.
• Downstaging for transplant: Patients outside Milan criteria can sometimes be brought inside using TACE or ablation before listing. Bridge therapy. Standard at experienced centres now, not a workaround.
• Living donor reality in India: Deceased donor availability is very limited here. Living donor liver transplant from a family member is the primary transplant pathway at most Indian centres. That changes the waiting time equation completely from what patients read about Western transplant programmes.

For patients who want to understand whether liver cancer is curable at their current stage, our blog on liver cancer curable explains what that means across stages and treatment types.

Dr. Sandeep Nayak has spent 24 years in surgical oncology. He holds DNB qualifications in Surgical Oncology and General Surgery, plus a fellowship in Laparoscopic and Robotic Onco Surgery. He performs robotic and laparoscopic hepatectomy for liver cancer resection, works closely with the liver transplant and hepatology teams for transplant assessment cases, and presents every liver cancer case to the tumour board so both resection and transplant are formally evaluated before any recommendation is made.

That joint evaluation at the first consultation, rather than being moved between departments after initial workup, is what prevents patients being funnelled into one pathway when the other might serve them better. Call +91 8104310753 to book your consultation.

Disclaimer: This blog is for informational purposes only and is not a substitute for professional medical advice.

For locally advanced esophageal cancer, chemo isn’t just given before surgery. It’s given to make surgery possible. The standard approach for operable esophageal cancer is neoadjuvant chemoradiotherapy first, then esophagectomy 6 to 12 weeks later. Chemo shrinks the tumour, downgrades the stage, clears microscopic spread, and turns an operation that couldn’t be done safely into one that can. The operability question gets reassessed after chemo, not decided before it.

According to Prof. Dr. Sandeep Nayak, Surgical Oncologist in India, “Neoadjuvant chemoradiotherapy before esophagectomy isn’t a delay in treatment. It is the treatment. We’re not waiting to see what happens. We’re actively shrinking the tumour, clearing the margins, improving the chances that the operation will achieve what we need it to achieve. The surgery after chemo is often a better, cleaner operation than surgery without it would have been.”

Several things shift during the neoadjuvant window. All of them matter.

• Tumour downstaging: Chemoradiotherapy shrinks the primary tumour and reduces lymph node involvement. A T3 tumour invading adjacent tissue can become a T2 confined to the oesophageal wall. That changes the operation entirely.
• Margin improvement: Smaller tumour means the surgeon has more room to achieve R0 resection, clear margins all round. Positive margins in oesophageal surgery are a major driver of recurrence.
• Pathological complete response: Around 25 to 30 percent of patients who complete neoadjuvant chemoradiotherapy show no remaining cancer on the surgical specimen. No viable cells at all. Surgery still usually goes ahead to confirm it.
• Fitness window: The 6 to 12 week gap between finishing chemoradiotherapy and operating also gives the patient time to recover nutritionally and physically. Oesophagectomy is a major operation. Going in stronger improves outcomes.

For patients whose oesophageal cancer requires minimally invasive resection, robotic cancer surgery brings thoracoscopic and laparoscopic precision to oesophagectomy, reducing blood loss and recovery time compared to open surgery.

Re-staging drives the decision. Several assessments run together.

• PET-CT re-staging: Shows metabolic activity in the tumour and lymph nodes after chemo. Significant reduction in uptake signals good response. Persistent high uptake raises the question of whether surgery is still the right next step.
• CT scan reassessment: Measures change in tumour size, local invasion and lymph node status. Compared directly against the pre-chemo staging scans to quantify response.
• Endoscopy and biopsy: Visual assessment of the oesophagus after chemoradiotherapy, with biopsies to check for residual cancer in the mucosa. Helps the surgeon plan the extent of resection.
• Patient fitness reassessment: Pulmonary function, nutritional status, weight, performance score all get reviewed before the surgical date is confirmed. Chemo takes a toll. Not everyone bounces back at the same rate.

For patients wanting to understand overall prognosis and what treatment response means for long-term outcomes, our blog on whether esophageal cancer curable covers the honest picture across stages.

Dr. Sandeep Nayak has spent 24 years in surgical oncology. He holds DNB qualifications in Surgical Oncology and General Surgery, plus a fellowship in Laparoscopic and Robotic Onco Surgery. He performs minimally invasive oesophagectomy using thoracoscopic and laparoscopic approaches, coordinates the neoadjuvant chemoradiotherapy plan with medical and radiation oncology, and re-stages every patient before confirming the surgical date. Every oesophageal cancer case goes through tumour board review before treatment begins.

That end-to-end coordination from neoadjuvant planning through to surgical recovery is what gives oesophageal cancer patients the best chance at an R0 resection and the strongest recovery from one of oncology’s most demanding operations. Call +91 8104310753 to book your consultation.

Disclaimer: This blog is for informational purposes only and is not a substitute for professional medical advice.

Most planned colon cancer surgeries don’t result in a permanent colostomy bag. For right hemicolectomy, left hemicolectomy and sigmoid colectomy in elective settings, the surgeon removes the diseased segment and rejoins the two ends directly. That’s called primary anastomosis and it avoids a bag entirely. Emergency situations change the picture. Perforation, obstruction, gross contamination or poor bowel preparation all raise the risk that a safe join isn’t possible and a temporary stoma becomes the safer option.

According to Prof. Dr. Sandeep Nayak, Surgical Oncologist in India, “For colon cancer, the bag question worries patients far more than the data warrants. Most elective right and left colon resections end with a direct join and no stoma. The cases where we create a stoma are the emergency presentations, the perforations, the unprepared bowels. When a patient comes in electively, staged properly, bowel prepared, that bag conversation usually doesn’t happen.”

Elective, prepared and uncomplicated. Those three conditions make avoidance realistic.

• Right hemicolectomy: Removes the right colon for cancers in the cecum, ascending colon or hepatic flexure. Small bowel joins to the remaining colon directly. No stoma in the vast majority of planned cases.
• Left hemicolectomy and sigmoid resection: Removes the left colon or sigmoid segment. Both ends of the remaining colon are joined. Stoma avoidable in elective settings with adequate bowel preparation and no gross contamination.
• Minimally invasive approach: Robotic and laparoscopic colon surgery reduces tissue trauma, blood loss and anastomosis tension. Better visualisation means a more precise join and fewer reasons to divert.
• Good patient selection: Well nourished, non-emergency patients with no sepsis and no prior pelvic radiation are the best candidates for primary anastomosis. These patients consistently avoid a bag.

For patients choosing minimally invasive colon surgery to reduce stoma risk, robotic cancer surgery offers the precision and tissue handling that supports safe anastomosis in even complex colonic resections.

Emergency and complicated cases shift the calculation sharply.

• Emergency surgery: Obstruction or perforation presenting as emergency colon surgery. The bowel is unprepared, often contaminated, and the anastomosis failure risk is too high to join safely. A Hartmann’s procedure, removing the diseased segment and creating a temporary end colostomy, is the safer call.
• Perforation with contamination: Free faecal contamination in the abdomen raises infection risk to a level where a new bowel join can’t be trusted to heal. Stoma protects the patient’s life. Reversal comes later once things are clean.
• Extensive or multifocal disease: Very advanced local disease involving adjacent organs or requiring wide resection may not leave enough bowel length for a safe tension-free join.
• Defunctioning loop: Sometimes the bowel join is technically done but the surgeon adds a temporary upstream loop ileostomy to divert stool while the anastomosis heals. Not a permanent bag. Reversed in 8 to 12 weeks.

For patients with rectal cancer where the colostomy question is even more loaded because of tumour proximity to the sphincter, our blog on rectal cancer colostomy walks through that specific decision in detail.

Dr. Sandeep Nayak has spent 24 years in surgical oncology. He holds DNB qualifications in Surgical Oncology and General Surgery, plus a fellowship in Laparoscopic and Robotic Onco Surgery. He performs robotic and laparoscopic colon resections with primary anastomosis as the standard goal in elective cases, and discusses the stoma question honestly with every patient before they go into theatre. Every colon cancer case is reviewed by the tumour board before the surgical plan is finalised.

That transparency before surgery, not just after, is what lets patients make genuinely informed decisions about their care. Getting to theatre knowing the stoma plan and the reversal plan if needed is a completely different experience from finding out in recovery. Call +91 8104310753 to book your consultation.

Disclaimer: This blog is for informational purposes only and is not a substitute for professional medical advice.

Prostate cancer surgery is not always necessary. Many prostate cancers are slow growing, low grade, and confined to the gland, and for these, active surveillance is a clinically accepted approach that avoids surgery entirely. Surgery becomes the right call when the cancer is localised, the patient is fit, and the goal is cure rather than long-term control. The decision is never automatic. It depends on PSA levels, Gleason score, staging, age and patient preference.

According to Prof. Dr. Sandeep Nayak, Surgical Oncologist in India, “Prostate cancer is one of the few cancers where doing nothing immediately is sometimes the most evidence-based choice. Many men are diagnosed with low-risk prostate cancer and live their entire lives without it becoming a problem. The surgical decision has to weigh the realistic risk from the cancer against the real side effects of the operation, and that’s a conversation the tumour board needs to have with each patient individually.”

Surgery suits specific patients in specific situations. Not every case.

• Localised disease: Cancer confined within the prostate capsule with no spread to lymph nodes or beyond. This is where radical prostatectomy has its strongest evidence base and curative intent.
• Younger, fit patients: Surgery is more suitable for men under 70 in good health who can tolerate general anaesthesia and recovery. Older men with significant comorbidities often do better with radiation or surveillance.
• Intermediate to high risk: Gleason score 7 or above, PSA between 10 and 20, or clinical stage T2. These features suggest the cancer is unlikely to stay slow and controlled without definitive treatment.
• Patient preference for removal: Some patients want the prostate out. Psychologically, removing the organ provides certainty that radiation or surveillance doesn’t. That’s a valid input into the decision.

For patients who choose surgery, robotic cancer surgery brings nerve-sparing precision that improves continence and erectile function recovery compared to open prostatectomy.

Three strong non-surgical options exist. Each has its own place.

• Active surveillance: Regular PSA testing, repeat biopsies and MRI monitoring without treatment. Standard for very low or low-risk disease. The cancer is watched, not ignored. Treatment begins only if it progresses.
• Radiation therapy: External beam radiation or brachytherapy. Equivalent survival outcomes to surgery in localised prostate cancer across multiple studies. Different side effect profile, not a lesser option.
• Hormone therapy: Used for advanced or metastatic disease, or alongside radiation for high-risk cases. Lowers testosterone that drives cancer growth. Not curative, but controls disease for years.
• Focal therapy: Emerging option for selected patients. Treats only the tumour within the gland using HIFU or cryotherapy. Preserves more function than full prostatectomy. Evidence is still growing.

For patients who do have surgery and want to understand what radiation after prostatectomy involves, our blog on prostate cancer radiation after robotic surgery walks through when it’s needed and why.

Dr. Sandeep Nayak has spent 24 years in surgical oncology. He holds DNB qualifications in Surgical Oncology and General Surgery, plus a fellowship in Laparoscopic and Robotic Onco Surgery. He performs nerve-sparing robotic radical prostatectomy for patients who need surgery, while actively supporting active surveillance for those who don’t. Every prostate cancer case is presented to the tumour board before any recommendation is made. That means no patient goes into surgery, surveillance or radiation without a collective clinical assessment behind the decision.

That approach matters in prostate cancer more than almost any other. The difference between overtreatment and undertreatment in this disease is real, and getting the recommendation right from the start saves patients from side effects they didn’t need and from delays they couldn’t afford. Call +91 8104310753 to book your consultation.

Disclaimer: This blog is for informational purposes only and is not a substitute for professional medical advice.